Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business acquisition

DataMEDS Acquires Helomics from Axe Compute

Analysis based on 11 articles · First reported Sep 15, 2026 · Last updated Sep 16, 2026

Sentiment
10
Attention
2
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The acquisition is a small-cap transaction that significantly boosts DataMEDS' market value and strategic positioning in the oncology diagnostics sector, as reflected by the sharp stock price increase. For Computex, the divestiture allows it to streamline operations and focus on its core AI infrastructure business while retaining exposure to Helomics' future potential.

healthcare artificial intelligence pharmaceuticals

DataMeds AI, Inc. (NASDAQ:MEDS) completed the acquisition of Helomics Corporation, an artificial intelligence cancer diagnostics laboratory business, from Computex Inc. (NASDAQ:AGPU) for a total purchase value of $1.5 million. The consideration consisted of common shares of DataMEDS and an acquisition note. Through the transaction, DataMEDS acquired Helomics' CLIA/CAP-certified clinical laboratory, all associated equipment, the Predictive Oncology contract research organization central lab services business, and $1.5 million in cash. The acquired business carries no third-party debt requiring repayment and no outstanding unpaid accounts payable outside of ongoing monthly operational expenses. DataMEDS intends to expand Helomics' capabilities beyond tumor molecular profiling and chemosensitivity testing into cancer screening, molecular profiling, traditional CLIA laboratory services, and optimized nutritional support for cancer patients. The acquisition provides DataMEDS with operational capital to support its Health Lives Here campaign and expands its services into cancer management, complementing its existing focus on GLP-1 agonist side effects and Long COVID. Computex, which will retain a shareholder position in Helomics, will focus its resources on scaling its core AI infrastructure business. Helomics was the final operating business remaining from Computex's former identity as Predictive Oncology Inc. prior to its name change in December 2025. Following the announcement, DataMEDS shares surged 87.20% to close at $1.62 on Tuesday, September 16, 2026, while Computex shares advanced 2.74%. DataMEDS recently implemented a 1-for-50 reverse stock split on May 26, 2026, and maintains a market capitalization of approximately $5 million.

100 DataMeds AI acquired Helomics
30 DataMeds AI implemented reverse stock split
priv
DataMEDS acquired Helomics for $1.5 million, expanding into cancer diagnostics and treatment. The acquisition and subsequent stock surge reflect positive market reception and strategic growth.
Importance 100.0 Sentiment 60.0
priv
Helomics was acquired by DataMEDS and will expand its cancer diagnostics and laboratory services under new ownership. The business is expected to benefit from DataMEDS' healthcare ecosystem and operational capital.
Importance 80.0 Sentiment 30.0
priv
Predictive Oncology's CRO central lab services business was part of the acquisition, now integrated into DataMEDS. It represents a key asset for drug development support.
Importance 40.0 Sentiment 10.0
per
As Interim Co-CEO of DataMEDS, Gerald Commissiong highlighted the strategic importance of the acquisition in expanding into oncology and improving patient outcomes.
Importance 30.0 Sentiment 0.0
per
As CEO of Computex, Chris Miglino emphasized the structured exit that maintains shareholder value and allows focus on AI infrastructure.
Importance 30.0 Sentiment 0.0
exch
Nasdaq is the exchange where DataMEDS and Computex are listed, and where the stock price movements occurred following the acquisition announcement.
Importance 10.0 Sentiment 0.0
govactor
The SEC will receive a Form 8-K filing from Computex detailing the transaction, ensuring regulatory compliance and disclosure.
Importance 10.0 Sentiment 0.0
priv
Corexa Health is a subsidiary of DataMEDS providing pharmacy services, and may benefit from expanded healthcare offerings post-acquisition.
Importance 5.0 Sentiment 0.0
priv
Tollo Health develops products distributed by DataMEDS' subsidiary, and could see synergies with the expanded cancer care services.
Importance 5.0 Sentiment 0.0
DataMeds AI parent ↔ Corexa Health DataMeds AI is the parent company that established Corexa Health as its pharmacy-focused division, leveraging its networ
DataMeds AI acquirer ↔ Tollo Health DataMeds AI has entered into a non-binding letter of intent to acquire a controlling interest in Tollo Health and is act
Nasdaq regulated exchange ↔ United States — United States Securities and Exchange Commission Nasdaq operates as a national securities exchange under the direct regulatory oversight of the U.S. Securities and Excha
Corexa Health distributor ↔ Tollo Health Corexa Health, a subsidiary of DataMeds AI, distributes select medical foods and supplements for Tollo Health through it
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.